{"id":"varivax-pe34-process","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions (erythema, swelling, pain)"},{"rate":"10-15","effect":"Fever"},{"rate":"3-5","effect":"Rash"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL5816807","moleculeType":null,"molecularWeight":"342.35"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains a weakened strain of varicella-zoster virus (Oka strain) that replicates in host cells sufficiently to trigger both cellular and humoral immune responses without causing clinical disease. This generates protective antibodies and cell-mediated immunity against the virus, reducing the risk of primary varicella infection and subsequent reactivation as herpes zoster.","oneSentence":"VARIVAX PE34 Process is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox and herpes zoster infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:12.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox)"},{"name":"Prevention of herpes zoster (shingles)"}]},"trialDetails":[{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VARIVAX® PE34 Process","genericName":"VARIVAX® PE34 Process","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"VARIVAX PE34 Process is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox and herpes zoster infection. Used for Prevention of varicella (chickenpox), Prevention of herpes zoster (shingles).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}